利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.038 秒)

    Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
    1.
    发明授权
    Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity 有权
    具有HIV整合酶抑制活性的双环氨基甲酰吡啶酮衍生物

    公开(公告)号：US07858788B2

    公开(公告)日：2010-12-28

    申请号：US11884686

    申请日：2006-02-20

    申请人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Yoshiyuki Taoda

    发明人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Yoshiyuki Taoda

    IPC分类号： C07D413/00 ,  C07D471/00

    CPC分类号： C07D471/04 ,  C07F9/6561

    摘要： Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and an agent, particularly an anti-HIV agent.A compound represented by the formula: (wherein Z1 is NR4 (R4 is hydrogen, optionally substituted lower alkyl etc.), O or CH2; Z2 is optionally substituted lower alkylene or optionally substituted lower alkenylene, each may be intervened by a heteroatom group selected from group consisting O, S, SO, SO2, NR5 (R5 is selected independently from the same substituent group of R4) —N═ and ═N—; R1 is hydrogen or lower alkyl; X is a single bond, a heteroatom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene each may be intervened by the heteroatom group; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted alkyl group etc.)

    摘要翻译： 是提供具有抗病毒活性，特别是HIV整合酶抑制活性的新型化合物和药剂，特别是抗HIV剂。 由下式表示的化合物（其中Z 1为NR 4（R 4为氢，任选取代的低级烷基等），O或CH 2; Z 2为任选取代的低级亚烷基或任选取代的低级亚烯基，各自可以被选自 来自由O，S，SO，SO 2，NR 5组成的基团（R 5独立地选自与R 4相同的取代基组）-N =和N - ; R 1是氢或低级烷基; X是单键， O，S，SO，SO 2和NH，或低级亚烷基或低级亚烯基各自可以被杂原子基团插入; R2是任选取代的芳基; R 3是氢，卤素，羟基，任选取代的烷基等）

    Hiv Integrase Inhibitors
    4.
    发明申请
    Hiv Integrase Inhibitors 审中-公开
    Hiv整合酶抑制剂

    公开(公告)号：US20080214527A1

    公开(公告)日：2008-09-04

    申请号：US11997786

    申请日：2006-07-28

    申请人： Takashi Kawasuji ,  Brian A. Johns

    发明人： Takashi Kawasuji ,  Brian A. Johns

    IPC分类号： A61K31/541 ,  C07D471/04 ,  A61P31/18 ,  A61K31/4375

    CPC分类号： C07D471/04

    摘要： The present invention features compounds that are HIV integrase inhibitors useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

    摘要翻译： 本发明的特征是可用于抑制HIV复制，预防和/或治疗HIV感染以及AIDS和/或ARC治疗中的HIV整合酶抑制剂的化合物。

    Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
    7.
    发明授权
    Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity 有权
    具有HIV整合酶抑制活性的多环氨基甲酰吡啶酮衍生物

    公开(公告)号：US08188271B2

    公开(公告)日：2012-05-29

    申请号：US12084128

    申请日：2006-10-26

    申请人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Teruhiko Taishi ,  Yoshiyuki Taoda

    发明人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Teruhiko Taishi ,  Yoshiyuki Taoda

    IPC分类号： C07D487/04 ,  C07D471/04 ,  A61K31/53 ,  A61P31/18

    CPC分类号： C07F9/6561 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D498/14

    摘要： Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R1 is hydrogen or lower alkyl; X is lower alkylene etc.; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B1 and B2 are such that any one of them is CR20R21, and the other is NR22 and, in this case, there is no broken line. When B2 is NR22, R4 and R22 may be connected together to form an optionally substituted heterocycle;When B2 is CHR21, R4 and R21 may be connected together to form an optionally substituted heterocycle.Alternatively, B1 and B2 are independently C, CR23 or N and, in this case, B1 and B2 may be taken together to form a heterocycle.R20, R21, R22 and R23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)

    摘要翻译： 提供具有抗病毒活性，特别是HIV整合酶抑制活性的新型化合物，以及药物组合物，特别是抗HIV剂。 （其中R1为氢或低级烷基; X为低级亚烷基等; R2为任选取代的芳基; R3为氢，卤素，羟基，任选取代的低级烷基等; R4为氢，任选取代的低级烷基，任选取代的环烷基， 任选取代的环烷基低级烷基，任选取代的芳基，任选取代的芳基低级烷基，任选取代的杂环基，任选取代的杂环低级烷基等;虚线表示存在或不存在键; B1和B2使得任何一个 它们是CR20R21，另一个是NR22，在这种情况下没有虚线，当B2是NR22时，R4和R22可以连接在一起形成任选取代的杂环;当B2是CHR21时，R4和R21可以是 连接在一起形成任选取代的杂环，或者B1和B2独立地为C，CR23或N，在这种情况下，B1和B2可以一起形成杂环R 20，R 21，R 22 和R 23独立地是氢，任选取代的低级烷基，任选取代的环烷基，任选取代的环烷基低级烷基等）

    Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity
    10.
    发明申请
    Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity 有权
    具有HIV整合酶抑制作用的聚酰胺酰吡啶酮衍生物

    公开(公告)号：US20090143356A1

    公开(公告)日：2009-06-04

    申请号：US12084128

    申请日：2006-10-26

    申请人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Teruhiko Taishi ,  Yoshiyuki Taoda

    发明人： Hiroshi Yoshida ,  Takashi Kawasuji ,  Teruhiko Taishi ,  Yoshiyuki Taoda

    IPC分类号： A61K31/553 ,  C07D487/04 ,  A61K31/53 ,  C07D413/06 ,  C07D498/14 ,  C07D498/12 ,  A61K31/5383 ,  A61K31/5377 ,  C07D487/14 ,  A61K31/551

    CPC分类号： C07F9/6561 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D498/14

    摘要： Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R1 is hydrogen or lower alkyl; X is lower alkylene etc.; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B1 and B2 are such that any one of them is CR20R21, and the other is NR22 and, in this case, there is no broken line. When B2 is NR22, R4 and R22 may be connected together to form an optionally substituted heterocycle;When B2 is CHR21, R4 and R21 may be connected together to form an optionally substituted heterocycle.Alternatively, B1 and B2 are independently C, CR23 or N and, in this case, B1 and B2 may be taken together to form a heterocycle.R20, R21, R22 and R23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)

    摘要翻译： 提供具有抗病毒活性，特别是HIV整合酶抑制活性的新型化合物，以及药物组合物，特别是抗HIV剂。 （其中R1为氢或低级烷基; X为低级亚烷基等; R2为任选取代的芳基; R3为氢，卤素，羟基，任选取代的低级烷基等; R4为氢，任选取代的低级烷基，任选取代的环烷基， 任选取代的环烷基低级烷基，任选取代的芳基，任选取代的芳基低级烷基，任选取代的杂环基，任选取代的杂环低级烷基等;虚线表示存在或不存在键; B1和B2使得任何一个 它们是CR20R21，另一个是NR22，在这种情况下没有虚线，当B2是NR22时，R4和R22可以连接在一起形成任选取代的杂环;当B2是CHR21时，R4和R21可以是 连接在一起形成任选取代的杂环，或者B1和B2独立地为C，CR23或N，在这种情况下，B1和B2可以一起形成杂环R 20，R 21，R 22 和R 23独立地是氢，任选取代的低级烷基，任选取代的环烷基，任选取代的环烷基低级烷基等）